Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that ...

Trials of cutting-edge cancer vaccines could kick off in the U.K. as soon as September, German Covid vaccine maker BioNTech announced on Friday, part of a new government partnership to fast track ...

In recent months, BioNTech has made significant strides in its oncology pipeline. The company's B7-H3 ADC, BNT324, has shown promising results in Phase 1/2 trials for patients with solid tumors ...

Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were “substantially higher” in people who got its new bivalent booster compared with people who ...

Shares of BioNTech fell 5.7% on Monday. Vaccine stocks are volatile after Moderna’s updated revenue guidance for 2025, which fell below analyst expectations. Get stock picks, daily rankings ...

BioNTech is bolstering its artificial intelligence and machine learning capabilities through the £362 million acquisition of InstaDeep, a startup whose technology has already supported the ...

Development of a cancer vaccine may be accelerated by BioNTech's COVID work. LONDON -- The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer ...

"BioNTech expects to grow its topline again in 2025," it said in a statement. BioNTech's German traded shares were down 0.9% at 1235 GMT as the target for this year fell short of an average ...

Penn sued BioNTech in August alleging the university was owed more in royalty payments for the use of the university's patented technology in a Covid-19 vaccine. Renowned Penn researchers win ...